Therapeutic Drug Monitoring Market: Growth, Size, Share, and Trends

Report Code MD 4185
Published in Dec, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti–Epileptic Drugs,Anti–Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029

Overview

The market for therapeutic drug monitoring is expected to grow at a compound annual growth rate (CAGR) of 8.4% from USD 2.30 billion in 2024 to USD 3.44 billion by 2029. This growth is brought on by a number of causes, such as the rise in chronic diseases like cancer, heart disease, epilepsy, and autoimmune conditions.In addition, the development of advanced and highly sensitive immunoassay methods including fluorescence, chemiluminescence, and ELISA is also contributing considerably to the expansion of the TDM industry. Additionally, more healthcare professionals have adopted TDM as a result of awareness campaigns highlighting its advantages of improving drug efficiency, treatment results, and patient safety. In many countries, regulatory agencies like the U.S. Standards regarding the use of drugs and diagnostic tools utilized in TOM are established by national and international bodies such as the FDA in the United States and EMA from the European Union. Recommendations of this nature specify indications of tests, data required to reach intended sensitivity, as well as general characteristics of performance that are to be aimed at. TDM practiced is of utmost importance and usually functions under recommendations stipulated nationally by health-oriented bodies and all medical boards regarding high-risk therapies for drugs amongst others such as oncology, cardiology, and neurological disorders.

Therapeutic Drug Monitoringmarket

Attractive Opportunities in the Therapeutic Drug Monitoringmarket

Asia Pacific

Market growth in Asia Pacific can be attributed to rising prevalence of chronic diseases and awareness among healthcare professionals and patients in APAC about the importance of drug safety.

The growth of this market can be attributed to the adoption of advanced technologies such as chromatography, mass spectrometry, and immunoassays, and ongoing urbanization and improvements in healthcare infrastructure in countries like China, India, and Southeast Asia

Trend toward personalized medicine, which tailors drug treatments to individual genetic profiles, is gaining traction in APAC and high growth potential of emerging markets are likely to promote significant growth opportunity of the market

The APAC therapeutic drug monitoring market is projected to reach USD 3.44 billion by 2029, at a CAGR of 8.4% during the forecast period.

North America is the largest regional market for therapeutic drug monitoring, due to the increasing investment by key players in the region

Global Therapeutic Drug Monitoringmarket Dynamics

DRIVER: The rising incidence of chronic conditions such as cancer, cardiovascular diseases, diabetes, and neurological disorders

The growing number of chronic diseases is one of the major factor driving the expansion of the Therapeutic Drug Monitoring (TDM) market. TDM is importantl to making sure drugs function properly, reducing side effects, and improving patient outcomes because disorders including cancer, heart disease, diabetes, and neurological diseases often require for extensive and complex pharmacological therapies. To meet the rising need for TDM solutions, the majority of companies are focusing on collaborations, development of new products, and planned investments. In 2023, for instance, Thermo Fisher cemented its position by acquiring Phadia, a renowned brand in immunoassay and allergy testing that also provides innovative diagnostic technologies that help drug monitoring in the treatment of chronic illnesses.

RESTRAINT: The Reluctance of small hospitals to offer therapeutic drug monitoring services

The major bottleneck of small and mid-size hospitals, in adopting TDM services is the high instrumentation cost, inappropriate infrastructure to support such a service, and limited access to major advanced diagnostic technologies. Some equipment, including the chromatography analysis, mass spectrometry, and immuno-assay platforms all require huge fixed costs and variable costs alike. Most small-sized hospitals, especially those operating in developing or rural areas, might not have the means for investment in such very high-cost technologies. In addition, the requirement for specialized personnel in the operation and interpretation of these complex systems further complicates matters. Poor reimbursement policies and insurance coverage for TDM services also discourage smaller hospitals, since the potential return on investment is usually low.

 

OPPORTUNITY: Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring

In a nutshell, various innovations in immunoassay technologies come with excellent prospects for increasing the speed and precision of drug monitoring in the TDM market. Advanced immunoassays are actually able to make drug monitoring real-time, both in and out of the hospital environment. Coupled with high-throughput capabilities, volume tested will increase, precision and speed increased with automation to streamline such processes. It will enhance general efficiency in the laboratories, reducing the time to get the results. Major players such as Roche, Abbott, Thermo Fisher, and Siemens head the pack with innovative systems tailored toward precision medicine and individualized care. More significantly, Abbott's ARCHITECT and Alinity immunoassay platforms are acclaimed for fast and precise TDM.

CHALLENGES: Higher maintenance of the therapeutic drug monitoringis major challenge for the market.

Some special sample handling is required in TDM testing, including proper collection of blood samples, storage, and transportation. Sample integrity faces major challenges due to changeable quality affecting results. The main drawbacks to new technology in relation to TDM, through the regulatory authorities for approval, usually take a good amount of time and are generally expensive. Other than that, regulatory requirements diverging in a different direction in regions like the US FDA and the European EMA further complicate expansion in the global market. Besides that, many LMICs are still not prepared with infrastructure that allows advanced TDM technologies like immunoassay platforms or high-throughput systems. In addition, laboratories are poorly equipped and face under-resourcing, including obsolete equipment. Moreover, even when available, high costs of TDM services are prohibitively expensive to low-income communities, reducing both access and utilization.

Global Therapeutic Drug Monitoringmarket Ecosystem Analysis

The ecosystem of the Therapeutic drug monitoringmarket comprises elements present in this market and defines these elements with a demonstration of the bodies involved. It includes manufacturers, distributors, research & product developers, and end users. The ecosystem of the overall Therapeutic drug monitoringmarket comprises the different elements and subdivisions present in it. Manufacturers include the organizations that are involved in the entire process of research, product development, optimization, and launch. Distributors include third parties and eCommerce sites, which are linked with organizations for the marketing of analyzers, reagents and kits, assays, and drugs. Research and product development includes in-house research facilities of organizations, contract research organizations, and contract development and manufacturing organizations, which play a key role in outsourcing research for product development to manufacturers.

Therapeutic Drug Monitoringmarket
 

By Therapeutic Area, Oncology segment is the fastest growing segment in therapeutic drug monitoring market during the forecast period.

Based on therapeutic area, the therapeutic drug monitoring market is segmented into Neurological Disorders, Cardiology, Infectious Diseases, Oncology, and Other Therapeutic Areas. Oncology segment is the fastest growing segment in this market. This growth is attributed to the global rise in cancer incidence, driven by aging populations, lifestyle changes, and environmental factors, is significantly increasing the demand for TDM in oncology, the shift towards personalized and precision medicine has heightened the importance of TDM in ensuring patients receive optimal chemotherapy doses.Furthermore, more accurate monitoring of drug effects and therapy responses has been made possible by advancements in cancer biomarkers. The need for accurate, customized medication monitoring in cancer care will keep driving expansion in the TDM industry as new therapies are developed.

By end user, hospital laboratories hold the largest share in the therapeutic drug monitoring market.

Based on the end user, the therapeutic drug monitoring market has been classified into Hospital Laboratories, Commercial & Private Laboratories, and Other End Users. The market for therapeutic drug monitoring was dominated in 2023 by the Hospital Laboratories. This growth is attributed to the increasing complexity of modern treatments, including polypharmacy, targeted therapies, and immunotherapies, requires precise drug monitoring to ensure optimal therapeutic outcomes and minimize adverse effects, the integration of advanced TDM technologies, such as high-throughput immunoassays, mass spectrometry, and automated systems, is improving the efficiency and accuracy of drug monitoring in hospital laboratories, healthcare systems are increasingly recognizing the value of TDM in optimizing drug therapies, leading to enhanced financial support and reimbursement for hospitals offering these services. Furthermore, advancements in laboratory management systems and automation are further boosting the operational efficiency of hospital laboratories.

North Amereica segment is the largest segment in the therapeutic drug monitoring market in 2023

Several of the key factors will create a path for solid growth in the North American TDM market. First, there is continuous innovation in the immunoassay technologies such as ELISA, chemiluminescence, fluorescence immunoassays, and chromatography-MS, leading to increased precision and efficient TDM. In addition to this, an increasing prevalence of chronic diseases such as cardiovascular conditions, neurological disorders, diabetes, and cancer demands the optimization of monitoring drugs, thus extending the scope of the market. This demand is supported by increasing investment in advanced TDM technologies by hospitals and clinical laboratories.

HIGHEST CAGR MARKET IN 2023
ASIA_PACIFIC FASTEST GROWING MARKET IN THE REGION
Therapeutic Drug Monitoringmarket

Recent Developments of Therapeutic Drug Monitoringmarket

  • In July 2024, Thermo Fisher launched an LC-MS solution which would take clinical research further by bundling high sensitivity and speed with throughput.
  • On its 2024 July announcement, Thermo Fisher Scientific has reached successful completion with the acquisition process with a leading provider of next-generation proteomics solutions, Olink Holding AB.
  • In January 2024, the automated clinical chemistry analyzer DXC 500 AU will be introduced at Medlab Middle East in Dubai by Beckman Coulter Diagnostics, a Danaher Corporation company.
  • Danaher purchased Abcam plc in December 2023. Abcam plc is a major global supplier of well validated antibodies, reagents, biomarkers, and tests for protein consumables.
  • In December 2023, a strategic 10-year value partnership has been formed between Siemens Healthineers and OU Health to provide the most up-to-date diagnostic and therapeutic equipment to Oklahomans.
  • In January 2023, Thermo Fisher Scientific Inc. announced the acquisition of The Binding Site Group, which is a global leader in specialty diagnostics.

Key Market Players

KEY PLAYERS IN THE THERAPEUTIC DRUG MONITORING MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Therapeutic Drug Monitoring Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD Million/Billion)
Segments covered Product, Technology, Drug Class, Therapeutic Area, Specimen, End User, and Region
Geographies covered North America (US & Canada), Europe (Germany, UK, France, Italy, Spain, and RoE), APAC (Japan, China, Australia, India, and the RoAPAC), Latin America, Middle East & Africa, and GCC Countries.

 

Key Questions Addressed by the Report

What are the drivers of the therapeutic drug monitoringmarket?
The drivers of the therapeutic drug monitoring market include increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, rising prevalence of cancer to drive adoption of therapeutic drug monitoring in oncology treatments, and importance of therapeutic drug monitoring in organ transplant procedures
Which type of product dominates the therapeutic drug monitoring market?
The consumables segment is dominating the therapeutic drug monitoring market.
Who are the end users of the therapeutic drug monitoring? Which end user is leading the market?
The therapeutic drug monitoring market is segmented into hospital laboratories, commercial & private laboratories, and other end users. The hospital laboratories segment accounted for the largest share of the therapeutic drug monitoringmarket in 2023.
Who are the key players in the therapeutic drug monitoringmarket?
The key players in the therapeutic drug monitoringmarket are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMérieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK).
Which region is lucrative for the therapeutic drug monitoring market?
The Asia Pacific market is expected to witness the highest growth during the forecast period.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Therapeutic Drug Monitoring Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
33
RESEARCH METHODOLOGY
37
EXECUTIVE SUMMARY
52
PREMIUM INSIGHTS
58
MARKET OVERVIEW
63
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Importance of therapeutic drug monitoring in organ transplant procedures
    - Use of therapeutic drug monitoring across various therapeutic fields
    - Increasing preference for precision medicine
    - Growing focus on R&D related to therapeutic drug monitoring
    - Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
    - Increasing prevalence of epilepsy
    - Rising prevalence of cancer
    RESTRAINTS
    - High capital investments
    - Reluctance of small hospitals to offer therapeutic drug monitoring services
    OPPORTUNITIES
    - Significant opportunities in BRICS countries
    - Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring
    - Integration of AI and machine learning
    CHALLENGES
    - Alternatives to conventional therapeutic drug monitoring
    - Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries
    - Shortage of skilled professionals
  • 5.3 PRICING ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
  • 5.7 REGULATORY LANDSCAPE
    NORTH AMERICA
    - US
    - Canada
    EUROPE
    ASIA PACIFIC
    - China
    - Japan
    - India
    LATIN AMERICA
    MIDDLE EAST
    AFRICA
  • 5.8 TRADE ANALYSIS
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES AND EVENTS IN 2025 AND 2026
  • 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.12 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGY
    - Enzyme-linked immunosorbent assay
    COMPLEMENTARY TECHNOLOGY
    - Liquid chromatography-mass spectrometry
    ADJACENT TECHNOLOGY
    - Electrophoresis
  • 5.13 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    THREAT OF SUBSTITUTES
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.15 INVESTMENT AND FUNDING SCENARIO
  • 5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE (AI) ON THERAPEUTIC DRUG MONITORING MARKET
THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT
102
  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    REPEAT PURCHASES AND HIGH USAGE TO DRIVE MARKET
  • 6.3 EQUIPMENT
    IMMUNOASSAY ANALYZERS
    - High efficiency to drive adoption
    CHROMATOGRAPHY & MS DETECTORS
    - Technological advancements to propel growth
    CLINICAL CHEMISTRY ANALYZERS
    - Increasing incidence of chronic and complex diseases to drive market
THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY
117
  • 7.1 INTRODUCTION
  • 7.2 IMMUNOASSAYS
    ENZYME-LINKED IMMUNOSORBENT ASSAYS
    - Accurate measurement of target-specific proteins to drive market
    CHEMILUMINESCENCE IMMUNOASSAYS
    - Rapid detection time and good specificity to support growth
    FLUORESCENCE IMMUNOASSAYS
    - High operability and better sensitivity of FIAs to drive market
    COLORIMETRIC IMMUNOASSAYS
    - Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
    OTHER IMMUNOASSAYS
  • 7.3 CHROMATOGRAPHY-MS
    LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
    - High accuracy to drive demand for LC-MS
    GAS CHROMATOGRAPHY-MASS SPECTROMETRY
    - Drawbacks of GC-MS to challenge market growth
  • 7.4 OTHER TECHNOLOGIES
THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS
146
  • 8.1 INTRODUCTION
  • 8.2 ANTIEPILEPTIC DRUGS
    HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
  • 8.3 ANTIARRHYTHMIC DRUGS
    INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
  • 8.4 IMMUNOSUPPRESSANT DRUGS
    INCREASING NUMBER OF ORGAN TRANSPLANTATION PROCEDURES TO DRIVE MARKET
  • 8.5 ANTIBIOTIC DRUGS
    TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND
  • 8.6 BRONCHODILATOR DRUGS
    RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
  • 8.7 PSYCHOACTIVE DRUGS
    RISING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
  • 8.8 OTHER DRUGS
THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA
170
  • 9.1 INTRODUCTION
  • 9.2 NEUROLOGICAL DISORDERS
    INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
  • 9.3 CARDIOLOGY
    HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
  • 9.4 INFECTIOUS DISEASES
    INCREASING PREVALENCE OF TB AND HEPATITIS TO BOOST DEMAND
  • 9.5 ONCOLOGY
    RISING BURDEN OF CANCER AND GROWING EMPHASIS ON PERSONALIZED MEDICINE TO PROPEL MARKET
  • 9.6 OTHER THERAPEUTIC AREAS
THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN
185
  • 10.1 INTRODUCTION
  • 10.2 BLOOD
    INNOVATIONS IN BLOOD SAMPLING TECHNIQUES TO DRIVE MARKET
  • 10.3 SALIVA
    DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
  • 10.4 OTHER SAMPLES
THERAPEUTIC DRUG MONITORING MARKET, BY END USER
193
  • 11.1 INTRODUCTION
  • 11.2 HOSPITAL LABORATORIES
    INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS PERFORMED TO DRIVE MARKET
  • 11.3 COMMERCIAL & PRIVATE LABORATORIES
    EXTENSIVE TEST MENU OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
  • 11.4 OTHER END USERS
THERAPEUTIC DRUG MONITORING MARKET, BY REGION
202
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    NORTH AMERICA: MACROECONOMIC OUTLOOK
    US
    - Increasing awareness regarding precision medicine to propel market
    CANADA
    - Availability of funding for research to offer growth opportunities
  • 12.3 EUROPE
  • 12.4 EUROPE: MACROECONOMIC OUTLOOK
    GERMANY
    - Rising prevalence of chronic medical conditions such as cancer and diabetes to support market growth
    UK
    - Increasing cases of chronic diseases to drive market
    FRANCE
    - Rising awareness of benefits of therapeutic drug monitoring to accelerate demand
    ITALY
    - Rising incidence of cancer to drive demand
    SPAIN
    - Adoption of technologically advanced immunoassays to boost market
    REST OF EUROPE
  • 12.5 ASIA PACIFIC
  • 12.6 ASIA PACIFIC: MACROECONOMIC OUTLOOK
    JAPAN
    - High prevalence of chronic diseases and advanced healthcare infrastructure to drive market
    CHINA
    - Rising number of organ transplants to boost market
    INDIA
    - Rising incidence of cancer to propel market
    AUSTRALIA
    - High healthcare expenditure and favorable government initiatives to propel market
    REST OF ASIA PACIFIC
  • 12.7 LATIN AMERICA
    INCREASING BURDEN OF CHRONIC CONDITIONS AND EXPANDING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
    LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 12.8 MIDDLE EAST & AFRICA
    INCREASING NUMBER OF CANCER PATIENTS TO DRIVE MARKET
    MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 12.9 GCC COUNTRIES
    GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
    GCC COUNTRIES: MACROECONOMIC OUTLOOK
COMPETITIVE LANDSCAPE
301
  • 13.1 OVERVIEW
  • 13.2 RIGHT TO WIN
  • 13.3 STRATEGIES ADOPTED BY KEY PLAYERS
  • 13.4 REVENUE ANALYSIS
  • 13.5 MARKET SHARE ANALYSIS
  • 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Product footprint
    - Technology footprint
    - End-user footprint
  • 13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - Detailed list of key startups/SMEs
  • 13.8 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 13.9 PRODUCT/BRAND COMPARISON
  • 13.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES
    DEALS
    EXPANSIONS
COMPANY PROFILES
316
  • 14.1 KEY PLAYERS
    ABBOTT
    - Business overview
    - Products offered
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    DANAHER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BIO-RAD LABORATORIES, INC.
    - Business overview
    - Products offered
    - Recent developments
    BIOMÉRIEUX SA
    - Business overview
    - Products offered
    BIOSYNEX SA
    - Business overview
    - Products offered
    - Recent developments
    GRIFOLS, S.A.
    - Business overview
    - Products offered
    - Recent developments
    EXAGEN INC.
    - Business overview
    - Products offered
    - Recent developments
    ARK DIAGNOSTICS, INC.
    - Business overview
    - Products offered
    R-BIOPHARM AG
    - Business overview
    - Products offered
    - Recent developments
    RANDOX LABORATORIES LTD.
    - Business overview
    - Products offered
  • 14.2 OTHER PLAYERS
    APDIA GROUP
    BBI SOLUTIONS
    EAGLE BIOSCIENCES, INC.
    JASEM LABORATORY SYSTEMS AND SOLUTIONS
    AALTO SCIENTIFIC, LTD.
    IMMUNDIAGNOSTIK AG
    UTAK
    SEKISUI MEDICAL CO., LTD.
    DIASYSTEM SCANDINAVIA AB
    CAMBRIDGE LIFE SCIENCES LIMITED
    CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
    BÜHLMANN LABORATORIES AG
    SJK GLOBAL, LLC
    EPITOPE DIAGNOSTICS, INC.
    QED BIOSCIENCE INC.
    BODITECH MED INC.
    IMMUNODIAGNOSTIC SYSTEMS
APPENDIX
372
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLE
373
  • 16.1 TABLE 1 RISK ASSESSMENT: THERAPEUTIC DRUG MONITORING MARKET
  • 16.2 TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING
  • 16.3 TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
  • 16.4 TABLE 4 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS, BY TYPE
  • 16.5 TABLE 5 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS, BY KEY PLAYER, 2022–2024
  • 16.6 TABLE 6 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS, BY KEY REGION
  • 16.7 TABLE 7 THERAPEUTIC DRUG MONITORING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • 16.8 TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 16.9 TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 16.10 TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 16.11 TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 16.12 TABLE 12 IMPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2019–2023 (USD MILLION)
  • 16.13 TABLE 13 EXPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2019–2023 (USD MILLION)
  • 16.14 TABLE 14 LIST OF CONFERENCES AND EVENTS, 2025–2026
  • 16.15 TABLE 15 THERAPEUTIC DRUG MONITORING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • 16.16 TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
  • 16.17 TABLE 17 KEY BUYING CRITERIA FOR END USERS
  • 16.18 TABLE 18 AI APPLICATIONS IN THERAPEUTIC DRUG MONITORING
  • 16.19 TABLE 19 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.20 TABLE 20 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 16.21 TABLE 21 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.22 TABLE 22 EUROPE: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.23 TABLE 23 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.24 TABLE 24 DRUGS MONITORED USING ANALYTICAL EQUIPMENT
  • 16.25 TABLE 25 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.26 TABLE 26 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 16.27 TABLE 27 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.28 TABLE 28 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.29 TABLE 29 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.30 TABLE 30 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2022–2029 (USD MILLION)
  • 16.31 TABLE 31 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.32 TABLE 32 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.33 TABLE 33 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.34 TABLE 34 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES, BY COMPANY, 2020–2024
  • 16.35 TABLE 35 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2022–2029 (USD MILLION)
  • 16.36 TABLE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.37 TABLE 37 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.38 TABLE 38 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.39 TABLE 39 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2022–2029 (USD MILLION)
  • 16.40 TABLE 40 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.41 TABLE 41 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.42 TABLE 42 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.43 TABLE 43 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.44 TABLE 44 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.45 TABLE 45 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION)
  • 16.46 TABLE 46 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.47 TABLE 47 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.48 TABLE 48 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.49 TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022–2029 (USD MILLION)
  • 16.50 TABLE 50 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.51 TABLE 51 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.52 TABLE 52 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.53 TABLE 53 EXAMPLES OF CLIA SYSTEMS
  • 16.54 TABLE 54 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS
  • 16.55 TABLE 55 THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION)
  • 16.56 TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.57 TABLE 57 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.58 TABLE 58 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.59 TABLE 59 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS
  • 16.60 TABLE 60 THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION)
  • 16.61 TABLE 61 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.62 TABLE 62 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.63 TABLE 63 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.64 TABLE 64 THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION)
  • 16.65 TABLE 65 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.66 TABLE 66 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.67 TABLE 67 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.68 TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION)
  • 16.69 TABLE 69 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.70 TABLE 70 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.71 TABLE 71 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.72 TABLE 72 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.73 TABLE 73 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY REGION, 2022–2029 (USD MILLION)
  • 16.74 TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.75 TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.76 TABLE 76 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.77 TABLE 77 THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
  • 16.78 TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.79 TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.80 TABLE 80 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.81 TABLE 81 THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
  • 16.82 TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.83 TABLE 83 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.84 TABLE 84 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.85 TABLE 85 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
  • 16.86 TABLE 86 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.87 TABLE 87 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.88 TABLE 88 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.89 TABLE 89 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.90 TABLE 90 DOSAGE GUIDELINES FOR NEW ANTIEPILEPTIC DRUGS IN ADOLESCENTS AND ADULTS
  • 16.91 TABLE 91 THERAPEUTIC DRUG MONITORING: LIMITATIONS FACED IN NEW ANTIEPILEPTIC DRUGS
  • 16.92 TABLE 92 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY REGION, 2022–2029 (USD MILLION)
  • 16.93 TABLE 93 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.94 TABLE 94 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.95 TABLE 95 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.96 TABLE 96 CLASSIFICATION OF ANTIARRHYTHMIC THERAPIES
  • 16.97 TABLE 97 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY REGION, 2022–2029 (USD MILLION)
  • 16.98 TABLE 98 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.99 TABLE 99 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.100 TABLE 100 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.101 TABLE 101 COMMONLY USED IMMUNOSUPPRESSANT DRUGS IN ORGAN TRANSPLANTS
  • 16.102 TABLE 102 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY REGION, 2022–2029 (USD MILLION)
  • 16.103 TABLE 103 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.104 TABLE 104 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.105 TABLE 105 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.106 TABLE 106 EXAMPLES OF ANTIBIOTIC DRUGS
  • 16.107 TABLE 107 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIAL LEVELS IN BIOFLUIDS
  • 16.108 TABLE 108 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY REGION, 2022–2029 (USD MILLION)
  • 16.109 TABLE 109 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.110 TABLE 110 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.111 TABLE 111 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.112 TABLE 112 EXAMPLES OF BRONCHODILATOR DRUGS
  • 16.113 TABLE 113 THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY REGION, 2022–2029 (USD MILLION)
  • 16.114 TABLE 114 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.115 TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.116 TABLE 116 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.117 TABLE 117 EXAMPLES OF PSYCHOACTIVE DRUGS
  • 16.118 TABLE 118 THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY REGION, 2022–2029 (USD MILLION)
  • 16.119 TABLE 119 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.120 TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.121 TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.122 TABLE 122 EXAMPLES OF OTHER DRUGS
  • 16.123 TABLE 123 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY REGION, 2022–2029 (USD MILLION)
  • 16.124 TABLE 124 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.125 TABLE 125 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.126 TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.127 TABLE 127 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.128 TABLE 128 PREVALENCE OF NEUROLOGICAL DISORDERS
  • 16.129 TABLE 129 THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
  • 16.130 TABLE 130 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.131 TABLE 131 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.132 TABLE 132 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.133 TABLE 133 THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY REGION, 2022–2029 (USD MILLION)
  • 16.134 TABLE 134 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.135 TABLE 135 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.136 TABLE 136 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.137 TABLE 137 THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • 16.138 TABLE 138 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.139 TABLE 139 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.140 TABLE 140 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.141 TABLE 141 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2040 (MILLION)
  • 16.142 TABLE 142 THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)
  • 16.143 TABLE 143 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.144 TABLE 144 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.145 TABLE 145 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.146 TABLE 146 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
  • 16.147 TABLE 147 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.148 TABLE 148 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.149 TABLE 149 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.150 TABLE 150 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.151 TABLE 151 THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • 16.152 TABLE 152 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.153 TABLE 153 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.154 TABLE 154 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.155 TABLE 155 THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • 16.156 TABLE 156 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.157 TABLE 157 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.158 TABLE 158 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.159 TABLE 159 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY REGION, 2022–2029 (USD MILLION)
  • 16.160 TABLE 160 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.161 TABLE 161 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.162 TABLE 162 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.163 TABLE 163 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.164 TABLE 164 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • 16.165 TABLE 165 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.166 TABLE 166 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.167 TABLE 167 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.168 TABLE 168 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • 16.169 TABLE 169 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.170 TABLE 170 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.171 TABLE 171 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.172 TABLE 172 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • 16.173 TABLE 173 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.174 TABLE 174 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.175 TABLE 175 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.176 TABLE 176 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 16.177 TABLE 177 NORTH AMERICA: KEY MACROINDICATORS
  • 16.178 TABLE 178 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.179 TABLE 179 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.180 TABLE 180 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.181 TABLE 181 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.182 TABLE 182 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.183 TABLE 183 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.184 TABLE 184 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.185 TABLE 185 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.186 TABLE 186 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.187 TABLE 187 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.188 TABLE 188 FDA NOVEL DRUG THERAPY APPROVALS FOR 2023
  • 16.189 TABLE 189 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS
  • 16.190 TABLE 190 US: NUMBER OF LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY TESTS, 2022–2029 (MILLION)
  • 16.191 TABLE 191 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.192 TABLE 192 US: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.193 TABLE 193 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.194 TABLE 194 US: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.195 TABLE 195 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.196 TABLE 196 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.197 TABLE 197 US: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.198 TABLE 198 US: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.199 TABLE 199 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.200 TABLE 200 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.201 TABLE 201 CANADA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.202 TABLE 202 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.203 TABLE 203 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.204 TABLE 204 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.205 TABLE 205 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.206 TABLE 206 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.207 TABLE 207 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.208 TABLE 208 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.209 TABLE 209 EUROPE: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • 16.210 TABLE 210 EUROPE: KEY MACROINDICATORS
  • 16.211 TABLE 211 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.212 TABLE 212 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.213 TABLE 213 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.214 TABLE 214 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.215 TABLE 215 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.216 TABLE 216 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.217 TABLE 217 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.218 TABLE 218 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.219 TABLE 219 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.220 TABLE 220 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.221 TABLE 221 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.222 TABLE 222 GERMANY: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.223 TABLE 223 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.224 TABLE 224 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.225 TABLE 225 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.226 TABLE 226 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.227 TABLE 227 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.228 TABLE 228 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.229 TABLE 229 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.230 TABLE 230 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.231 TABLE 231 UK: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.232 TABLE 232 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.233 TABLE 233 UK: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.234 TABLE 234 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.235 TABLE 235 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.236 TABLE 236 UK: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.237 TABLE 237 UK: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.238 TABLE 238 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.239 TABLE 239 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.240 TABLE 240 FRANCE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.241 TABLE 241 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.242 TABLE 242 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.243 TABLE 243 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.244 TABLE 244 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.245 TABLE 245 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.246 TABLE 246 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.247 TABLE 247 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.248 TABLE 248 ITALY: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • 16.249 TABLE 249 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.250 TABLE 250 ITALY: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.251 TABLE 251 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.252 TABLE 252 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.253 TABLE 253 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.254 TABLE 254 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.255 TABLE 255 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.256 TABLE 256 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.257 TABLE 257 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.258 TABLE 258 SPAIN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • 16.259 TABLE 259 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.260 TABLE 260 SPAIN: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.261 TABLE 261 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.262 TABLE 262 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.263 TABLE 263 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.264 TABLE 264 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.265 TABLE 265 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.266 TABLE 266 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.267 TABLE 267 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.268 TABLE 268 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.269 TABLE 269 REST OF EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.270 TABLE 270 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.271 TABLE 271 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.272 TABLE 272 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.273 TABLE 273 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.274 TABLE 274 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.275 TABLE 275 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.276 TABLE 276 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.277 TABLE 277 ASIA PACIFIC: KEY MACROINDICATORS
  • 16.278 TABLE 278 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 16.279 TABLE 279 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.280 TABLE 280 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.281 TABLE 281 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.282 TABLE 282 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.283 TABLE 283 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.284 TABLE 284 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.285 TABLE 285 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.286 TABLE 286 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.287 TABLE 287 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.288 TABLE 288 JAPAN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • 16.289 TABLE 289 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.290 TABLE 290 JAPAN: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.291 TABLE 291 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.292 TABLE 292 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.293 TABLE 293 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.294 TABLE 294 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.295 TABLE 295 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.296 TABLE 296 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.297 TABLE 297 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.298 TABLE 298 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.299 TABLE 299 CHINA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.300 TABLE 300 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.301 TABLE 301 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.302 TABLE 302 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.303 TABLE 303 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.304 TABLE 304 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.305 TABLE 305 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.306 TABLE 306 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.307 TABLE 307 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.308 TABLE 308 INDIA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.309 TABLE 309 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.310 TABLE 310 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.311 TABLE 311 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.312 TABLE 312 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.313 TABLE 313 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.314 TABLE 314 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.315 TABLE 315 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.316 TABLE 316 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.317 TABLE 317 AUSTRALIA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.318 TABLE 318 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.319 TABLE 319 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.320 TABLE 320 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.321 TABLE 321 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.322 TABLE 322 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.323 TABLE 323 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.324 TABLE 324 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.325 TABLE 325 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.326 TABLE 326 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.327 TABLE 327 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.328 TABLE 328 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.329 TABLE 329 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.330 TABLE 330 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.331 TABLE 331 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.332 TABLE 332 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.333 TABLE 333 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.334 TABLE 334 LATIN AMERICA: KEY MACROINDICATORS
  • 16.335 TABLE 335 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.336 TABLE 336 LATIN AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.337 TABLE 337 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.338 TABLE 338 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.339 TABLE 339 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.340 TABLE 340 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.341 TABLE 341 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.342 TABLE 342 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.343 TABLE 343 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.344 TABLE 344 MIDDLE EAST & AFRICA: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045
  • 16.345 TABLE 345 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • 16.346 TABLE 346 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.347 TABLE 347 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.348 TABLE 348 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.349 TABLE 349 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.350 TABLE 350 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.351 TABLE 351 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.352 TABLE 352 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.353 TABLE 353 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.354 TABLE 354 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.355 TABLE 355 GCC COUNTRIES: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045
  • 16.356 TABLE 356 GCC COUNTRIES: KEY MACROINDICATORS
  • 16.357 TABLE 357 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • 16.358 TABLE 358 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 16.359 TABLE 359 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 16.360 TABLE 360 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.361 TABLE 361 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION)
  • 16.362 TABLE 362 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION)
  • 16.363 TABLE 363 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • 16.364 TABLE 364 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION)
  • 16.365 TABLE 365 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 16.366 TABLE 366 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021–NOVEMBER 2024
  • 16.367 TABLE 367 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION
  • 16.368 TABLE 368 THERAPEUTIC DRUG MONITORING MARKET: REGION FOOTPRINT
  • 16.369 TABLE 369 THERAPEUTIC DRUG MONITORING MARKET: PRODUCT FOOTPRINT
  • 16.370 TABLE 370 THERAPEUTIC DRUG MONITORING MARKET: TECHNOLOGY FOOTPRINT
  • 16.371 TABLE 371 THERAPEUTIC DRUG MONITORING MARKET: END-USER FOOTPRINT
  • 16.372 TABLE 372 THERAPEUTIC DRUG MONITORING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • 16.373 TABLE 373 THERAPEUTIC DRUG MONITORING MARKET: PRODUCT LAUNCHES, JANUARY 2021–NOVEMBER 2024
  • 16.374 TABLE 374 THERAPEUTIC DRUG MONITORING MARKET: DEALS, JANUARY 2021–NOVEMBER 2024
  • 16.375 TABLE 375 THERAPEUTIC DRUG MONITORING MARKET: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • 16.376 TABLE 376 ABBOTT: COMPANY OVERVIEW
  • 16.377 TABLE 377 ABBOTT: PRODUCTS OFFERED
  • 16.378 TABLE 378 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • 16.379 TABLE 379 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • 16.380 TABLE 380 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • 16.381 TABLE 381 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • 16.382 TABLE 382 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • 16.383 TABLE 383 CURRENCY CONVERSION FOR F. HOFFMANN-LA ROCHE LTD.
  • 16.384 TABLE 384 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • 16.385 TABLE 385 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • 16.386 TABLE 386 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–OCTOBER 2024
  • 16.387 TABLE 387 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • 16.388 TABLE 388 CURRENCY CONVERSION FOR SIEMENS HEALTHINEERS AG
  • 16.389 TABLE 389 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • 16.390 TABLE 390 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • 16.391 TABLE 391 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–OCTOBER 2024
  • 16.392 TABLE 392 DANAHER CORPORATION: COMPANY OVERVIEW
  • 16.393 TABLE 393 DANAHER CORPORATION: PRODUCTS OFFERED
  • 16.394 TABLE 394 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • 16.395 TABLE 395 DANAHER CORPORATION: DEALS, JANUARY 2021–OCTOBER 2024
  • 16.396 TABLE 396 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • 16.397 TABLE 397 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • 16.398 TABLE 398 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • 16.399 TABLE 399 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • 16.400 TABLE 400 BIOMÉRIEUX SA: COMPANY OVERVIEW
  • 16.401 TABLE 401 CURRENCY CONVERSION FOR BIOMÉRIEUX SA
  • 16.402 TABLE 402 BIOMÉRIEUX SA: PRODUCTS OFFERED
  • 16.403 TABLE 403 BIOSYNEX SA: COMPANY OVERVIEW
  • 16.404 TABLE 404 CURRENCY CONVERSION FOR BIOSYNEX SA
  • 16.405 TABLE 405 BIOSYNEX SA: PRODUCTS OFFERED
  • 16.406 TABLE 406 BIOSYNEX SA: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • 16.407 TABLE 407 BIOSYNEX SA: DEALS, JANUARY 2021–OCTOBER 2024
  • 16.408 TABLE 408 GRIFOLS, S.A.: COMPANY OVERVIEW
  • 16.409 TABLE 409 GRIFOLS, S.A.: PRODUCTS OFFERED
  • 16.410 TABLE 410 GRIFOLS, S.A.: DEALS, JANUARY 2021–OCTOBER 2024
  • 16.411 TABLE 411 EXAGEN INC.: COMPANY OVERVIEW
  • 16.412 TABLE 412 EXAGEN INC.: PRODUCTS OFFERED
  • 16.413 TABLE 413 EXAGEN INC.: DEALS, JANUARY 2021–OCTOBER 2024
  • 16.414 TABLE 414 ARK DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • 16.415 TABLE 415 ARK DIAGNOSTICS, INC.: PRODUCTS OFFERED
  • 16.416 TABLE 416 R-BIOPHARM AG: COMPANY OVERVIEW
  • 16.417 TABLE 417 R-BIOPHARM AG: PRODUCTS OFFERED
  • 16.418 TABLE 418 R-BIOPHARM AG: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • 16.419 TABLE 419 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW
  • 16.420 TABLE 420 RANDOX LABORATORIES LTD.: PRODUCTS OFFERED
  • 16.421 TABLE 421 APDIA GROUP: COMPANY OVERVIEW
  • 16.422 TABLE 422 BBI SOLUTIONS: COMPANY OVERVIEW
  • 16.423 TABLE 423 EAGLE BIOSCIENCES, INC.: COMPANY OVERVIEW
  • 16.424 TABLE 424 JASEM LABORATORY SYSTEMS AND SOLUTIONS: COMPANY OVERVIEW
  • 16.425 TABLE 425 AALTO SCIENTIFIC, LTD.: COMPANY OVERVIEW
  • 16.426 TABLE 426 IMMUNDIAGNOSTIK AG: COMPANY OVERVIEW
  • 16.427 TABLE 427 UTAK: COMPANY OVERVIEW
  • 16.428 TABLE 428 SEKISUI MEDICAL CO., LTD.: COMPANY OVERVIEW
  • 16.429 TABLE 429 DIASYSTEM SCANDINAVIA AB: COMPANY OVERVIEW
  • 16.430 TABLE 430 CAMBRIDGE LIFE SCIENCES LIMITED: COMPANY OVERVIEW
  • 16.431 TABLE 431 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: COMPANY OVERVIEW
  • 16.432 TABLE 432 BÜHLMANN LABORATORIES AG: COMPANY OVERVIEW
  • 16.433 TABLE 433 SJK GLOBAL, LLC: COMPANY OVERVIEW
  • 16.434 TABLE 434 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • 16.435 TABLE 435 QED BIOSCIENCE INC.: COMPANY OVERVIEW
  • 16.436 TABLE 436 BODITECH MED INC.: COMPANY OVERVIEW
  • 16.437 TABLE 437 IMMUNODIAGNOSTIC SYSTEMS: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION
  • FIGURE 2 THERAPEUTIC DRUG MONITORING MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 6 ESTIMATING GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 TOP-DOWN APPROACH
  • FIGURE 9 DATA TRIANGULATION
  • FIGURE 10 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THERAPEUTIC DRUG MONITORING MARKET
  • FIGURE 17 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE MARKET
  • FIGURE 18 ANTIEPILEPTIC DRUGS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
  • FIGURE 19 CHINA TO REGISTER HIGHEST GROWTH FROM 2024 TO 2029
  • FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 22 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 UK: NUMBER OF DECEASED DONORS AND TRANSPLANTS, APRIL 1, 2020–MARCH 31, 2024
  • FIGURE 24 PERSONALIZED MEDICINE APPROVALS BY US FDA, 2015–2022
  • FIGURE 25 NUMBER OF RESEARCH PUBLICATIONS ON THERAPEUTIC DRUG MONITORING, 2015–2021
  • FIGURE 26 INCIDENCE OF DIABETES, BY REGION, 2021 VS. 2030 VS. 2045 (MILLION)
  • FIGURE 27 NUMBER OF US ADULTS WITH ACTIVE EPILEPSY, BY AGE GROUP (THOUSAND)
  • FIGURE 28 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION)
  • FIGURE 29 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2014–2021
  • FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • FIGURE 31 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
  • FIGURE 32 THERAPEUTIC DRUG MONITORING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 33 PATENT ANALYSIS FOR THERAPEUTIC DRUG MONITORING, JANUARY 2015–DECEMBER 2023
  • FIGURE 34 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING
  • FIGURE 35 THERAPEUTIC DRUG MONITORING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
  • FIGURE 37 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 38 INVESTMENT AND FUNDING SCENARIO
  • FIGURE 39 US: PATIENTS ON WAITING LIST VS. TRANSPLANTS PERFORMED, BY ORGAN, 2023
  • FIGURE 40 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
  • FIGURE 41 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
  • FIGURE 42 THERAPEUTIC DRUG MONITORING MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD BILLION)
  • FIGURE 43 THERAPEUTIC DRUG MONITORING MARKET SHARE ANALYSIS, 2023
  • FIGURE 44 THERAPEUTIC DRUG MONITORING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 45 THERAPEUTIC DRUG MONITORING MARKET: COMPANY FOOTPRINT
  • FIGURE 46 THERAPEUTIC DRUG MONITORING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 47 EV/EBITDA OF KEY VENDORS
  • FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 49 THERAPEUTIC DRUG MONITORING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 54 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2023)
  • FIGURE 56 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2023)
  • FIGURE 57 BIOSYNEX SA: COMPANY SNAPSHOT (2023)
  • FIGURE 58 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 59 EXAGEN INC.: COMPANY SNAPSHOT (2023)

The study involved major activities in estimating the current market size for the therapeutic drug monitoring market. Exhaustive secondary research was done to collect information on the therapeutic drug monitoring industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the therapeutic drug monitoring market.

Secondary Research

The market for the companies offering therapeutic drug monitoring solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

In the secondary research process, various secondary sources were referred to for identifying and collecting information related to the study. Secondary sources included annual reports, press releases, and investor presentations of blockchain vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

Primary Research

In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the blockchain market. After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also conducted to identify the segmentation types, industry trends, competitive landscape of therapeutic drug monitoring solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

In the complete market engineering process, the top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

Therapeutic Drug Monitoringmarket

*C-level primaries include CEOs, CFOs, COOs, and VPs.

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell culture market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Therapeutic Drug Monitoringmarket

Data Triangulation

After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Therapeutic drug monitoring (TDM) measures the concentration of specific drugs in body fluids, which helps manage drug therapy to cure, alleviate, or prevent diseases. TDM is used mainly for monitoring drugs with narrow therapeutic ranges, drugs with marked pharmacokinetic variability, medications for which target concentrations are difficult to monitor, and drugs known to cause therapeutic and adverse effects.

Stakeholders

  • Therapeutic Drug Monitoring Product Manufacturers
  • Healthcare Service Providers
  • Research Associations
  • Research Institutes
  • Venture Capitalists and Investors
  • Various Research and Consulting Companies
  • Pharmaceutical and Biopharmaceutical Companies
  • Diagnostic Associations
  • Clinical Laboratories
  • Suppliers/Distributors of Therapeutic Drug Monitoring Products and Consumables
  • Hospitals
  • Government and Non-governmental Regulatory Authorities

Report Objectives

  • To define, describe, and forecast the therapeutic drug monitoring market based on – product, technology, drug class, therapeutic area, specimen, end user, and region.
  • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market.
  • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries.
  • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market.
  • To profile the key players and comprehensively analyze their market sizes and core competencies
  • To track and analyze competitive developments such as product enhancements and new product launches, acquisitions, and partnerships & collaborations in the market globally.

Previous Versions of this Report

Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers), Technology, Class of drugs, End user and Region - Global Forecast to 2026

Report Code MD 4185
Published in Feb, 2023, By MarketsandMarkets™

Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers), Technology, Class of drugs, End user and Region - Global Forecast to 2026

Report Code MD 4185
Published in Feb, 2022, By MarketsandMarkets™

Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibiotic Drugs, Bronchodilator Drugs), End User - Global Forecast to 2025

Report Code MD 4185
Published in Aug, 2020, By MarketsandMarkets™

Therapeutic Drug Monitoring Market by Product (Consumable, Equipment (Immunoassay analyzer)), Technology (Fluorescence Immunoassay, Radioimmunoassay, GCMS), Class of drugs (Antibiotics, Bronchodilators), End User (Hospital Lab) - Global Forecast to 2023

Report Code MD 4185
Published in Aug, 2018, By MarketsandMarkets™

Therapeutic Drug Monitoring Market by Product (Consumable, Equipment (Immunoassay analyzer)), Technology (Fluorescence Immunoassay, Radioimmunoassay, GCMS), Class of drugs (Antibiotics, Bronchodilators), End User (Hospital Lab) - Global Forecast to 2023

Report Code MD 4185
Published in Mar, 2016, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Therapeutic Drug Monitoring Market

DMCA.com Protection Status